跳至主要内容
临床试验/EUCTR2014-005367-32-IT
EUCTR2014-005367-32-IT进行中(未招募)1 期

PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN - PROMISE

FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点目标入组 208 人开始时间: 2017年3月17日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
208

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Diagnosis of, probable, probable laboratory supported or definite sporadic (SALS) or familiar (FALS) ALS according to the revised El Escorial criteria; 2) age >18 yrs; 3) onset =18 months before randomization; 4) sVC =70% in spinal onset; 5) riluzole 100 mg/day or no riluzole; 6) written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 1
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 166
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 42

排除标准

  • 1) PEG, NIV or tracheotomy; 3) known heart, renal or liver failure; 3) known intolerance to alfa2agonists; 4) known conditions at risk for cardiovascular disorders or symptomatic hypotension; 5) participation in a clinical trial within 3 months prior to the screening; 6) cognitive impairment defined by the Edinburg Cognitive and Behavior ALS Screen (ECAS) scale

研究者

相似试验